Prostate Cancer

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Latest News

Hypofractionation is Noninferior to Conventional Fractionation Radiotherapy in Low-Risk Prostate Cancer

By Megan Hollasch

June 12th 2024

Hypofractionation radiotherapy was noninferior to conventional fractionation radiotherapy for the treatment of patients with low-risk prostate cancer.

JNJ-6420 Elicits Responses in mCRPC, But Safety Concerns Arise

By Jordyn Sava

June 10th 2024

Daniel P. Petrylak, MD, of Yale School of Medicine

ARV-766 Demonstrates Clinical Activity in AR LBD–Mutated Metastatic CRPC

By Jonah Feldman

June 10th 2024

Pembrolizumab With Platinum-Based Therapy is Safe and Efficacious in PSCC

By Benjiman Saylor

June 7th 2024

Intensification With Apalutamide/ADT Improves PSA PFS in Biochemically Recurrent Prostate Cancer

By Benjamin Saylor

June 6th 2024

Latest CME Events & Activities

Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?

Advances In™: Targeting PSMA to Advance Diagnosis And Management Of Patients With Prostate Cancer

Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer

Community Practice Connections™: Controversies and Conversations About HER2- Expressing Breast Cancer…Advances in Management of HER2-Low to -Positive Disease

2023 ASCO Direct™ Highlights: Practice-Changing Data From the Leading Oncology Conference

Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board

Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?

Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!

Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer

Dialogues With the Surgeon on Integration of Systemic Therapies in Perioperative Settings for NSCLC: Looking at EGFR, ALK, IO, and Beyond…

Tumor-Infiltrating Lymphocyte Therapy Advances Into Melanoma

More News

The Rapid Reporter: April 2007

By By Diane West

August 13th 2010

This month we report on presentations made at the BIO (Biotechnology Industry Organization)CEO & Investor Conference (February 11-14, 2007, New York, NY).

AUA Updates Prostate Cancer Guidelines

By By John D. Zoidis, MD

July 12th 2010

The first revision in 12 years, the new guidelines are based on a growing body of evidence-based research and emphasize communication with the patient regarding risk, treatment options, and potential outcomes.

Patient Recruitment Completed for First Phase III Clinical Trial of GVAX Immunotherapy for Prostate Cancer

By Onclive Team

July 8th 2010

Cell Genesys has announced that it has completed recruitment of more than 600 patients into VITAL-1, the first of two ongoing Phase III clinical trials of GVAX immunotherapy for prostate cancer.

Provenge Takes Personalized Care to a New Level

By Ed Rabinowitz

June 12th 2010

Provenge becomes the first immunotherapy vaccine against cancer to win FDA approval

Judge Rules Myriad Cannot Patent BRCA1 and BRCA2-Genes

By Jason Broderick

April 4th 2010

A US district court invalidated 7 of 23 of Myriad Genetics, Inc's patents on the BRCA1 and BRCA2 genes, which confer an increased risk of developing breast, ovarian, and prostate cancers.

GPS for the Body: Treating a Moving Target

By Eric M. Horwitz, MD

February 25th 2009

A common treatment option for prostate cancer is radiation therapy, which is as effective in treating the disease as surgical removal of the prostate.

...

106 107 108 109 110 111 >